-

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Intercept Pharmaceuticals, Inc. – ICPT

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) resulting from allegations that Intercept may have issued materially misleading business information to the investing public.

On October 8, 2020, news outlets reported that Intercept was “facing an investigation from the U.S. Food and Drug Administration over the potential risk of liver injury in patients taking Ocaliva, [Intercept’s] treatment for primary biliary cholangitis, a rare, chronic liver disease.”

On this news, Intercept’s stock price fell $3.30 per share, or 8%, to close at $37.69 per share on October 8, 2020, damaging investors.

Rosen Law Firm is preparing a securities lawsuit on behalf of Intercept shareholders. If you purchased securities of Intercept please visit the firm’s website at http://www.rosenlegal.com/cases-register-1973.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at mailto:pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The Rosen Law Firm, P.A.

NASDAQ:ICPT

Release Versions

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Social Media Profiles
More News From The Rosen Law Firm, P.A.

Rosen Law Firm Encourages Amdocs Limited Investors to Inquire About Securities Class Action Investigation - DOX

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Amdocs Limited (NASDAQ: DOX) resulting from allegations that Amdox may have issued materially misleading business information to the investing public.So What: If you purchased Amdocs securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen...

Rosen Law Firm Encourages FreightCar America, Inc. Investors to Inquire About Securities Class Action Investigation - RAIL

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of FreightCar America, Inc. (NASDAQ: RAIL) resulting from allegations that FreightCar America may have issued materially misleading business information to the investing public.So What: If you purchased FreightCar America securities you may be entitled to compensation without payment of any out of pocket fees or costs through a con...

BBNX Deadline Today: Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026. Beta Bionics describes itself as a “commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes.”For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Al...
Back to Newsroom